Tanwandee 2012

Methods	Randomised clinical phase II trial
Participants	24 adults with chronic hepatitis C, genotype 1, who were naive to antiviral treatment. Country: Thailand Exclusion criteria: not described.
Interventions	Experimental group: oral 200 mg, 400 mg of BIT225 for 28 days. Control group: placebo. Co‐intervention: IFN alfa 2b and RBV for a total of 48 weeks.
Outcomes	SVR, safety, pharmacokinetics.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial was described as being placebo‐blinded, but it was unclear how the blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The trial was described as being placebo‐blinded, but it was unclear how the blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No data
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	The trial was funded by Bristol‐Myers Squibb
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias